KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Accounts Payables (2018 - 2025)

Historic Accounts Payables for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $6.8 million.

  • Vir Biotechnology's Accounts Payables fell 626.97% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 626.97%. This contributed to the annual value of $5.1 million for FY2024, which is 1978.21% down from last year.
  • Latest data reveals that Vir Biotechnology reported Accounts Payables of $6.8 million as of Q3 2025, which was down 626.97% from $12.2 million recorded in Q2 2025.
  • Vir Biotechnology's 5-year Accounts Payables high stood at $12.4 million for Q2 2023, and its period low was $2.7 million during Q3 2022.
  • In the last 5 years, Vir Biotechnology's Accounts Payables had a median value of $6.5 million in 2021 and averaged $7.2 million.
  • As far as peak fluctuations go, Vir Biotechnology's Accounts Payables plummeted by 8028.03% in 2021, and later soared by 19600.11% in 2022.
  • Vir Biotechnology's Accounts Payables (Quarter) stood at $6.5 million in 2021, then dropped by 1.52% to $6.4 million in 2022, then fell by 1.37% to $6.3 million in 2023, then decreased by 19.78% to $5.1 million in 2024, then skyrocketed by 34.76% to $6.8 million in 2025.
  • Its last three reported values are $6.8 million in Q3 2025, $12.2 million for Q2 2025, and $3.7 million during Q1 2025.